Literature DB >> 6182610

In vitro stimulation of lymphocytes in leprosy patients, healthy contacts of leprosy patients, and subjects not exposed to leprosy. Comparison of an antigen fraction prepared from Mycobacterium leprae and tuberculin-purified protein derivative.

O Closs, L J Reitan, K Negassi, M Harboe, A Belehu.   

Abstract

In vitro lymphocyte stimulation was performed on peripheral blood lymphocytes from 48 leprosy patients, 15 healthy contacts of leprosy patients, and 16 normal controls who lived in a leprosy-free area and who had not been exposed to leprosy. Tuberculin PPD and an antigen fraction. MLW 1, prepared from M. leprae, were used as stimulants. The MLW 1 preparation contained one antibody-precipitable component when tested in crossed immunoelectrophoresis against a polyvalent anti-M. leprae immunoglobulin preparation, namely the ML 7 antigen. MLW 1 induced strong lymphocyte responses in patients with tuberculoid leprosy and healthy contacts of leprosy patients, but only a weak or no responses in lepromatous leprosy patients and non-exposed controls. A marked depression of the response to tuberculin PPD was observed in lepromatous leprosy patients. The specificity of the MLW 1 antigen is discussed, and a new estimator of specific lymphocyte stimulation, the delta cpm', is introduced.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6182610     DOI: 10.1111/j.1365-3083.1982.tb00704.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  13 in total

1.  Antibodies to Mycobacterium tuberculosis-specific epitopes in lepromatous leprosy.

Authors:  G Bothamley; J S Beck; W Britton; A Elsaghier; J Ivanyi
Journal:  Clin Exp Immunol       Date:  1991-12       Impact factor: 4.330

Review 2.  Biological, chemical, immunological and staining properties of bacteria isolated from tissues of leprosy patients.

Authors:  C Cocito; J Delville
Journal:  Eur J Epidemiol       Date:  1985-09       Impact factor: 8.082

Review 3.  Early events in the host-parasite relationship and immune response in clinical leprosy: its possible importance for leprosy control.

Authors:  G Bjune; O Closs; R S Barnetson
Journal:  Clin Exp Immunol       Date:  1983-11       Impact factor: 4.330

4.  In vitro stimulation of lymphocytes with an antigen fraction prepared from Mycobacterium leprae and tuberculin PPD in contacts and non-contacts of leprosy patients.

Authors:  L J Reitan; O Closs
Journal:  Clin Exp Immunol       Date:  1984-08       Impact factor: 4.330

5.  Low T lymphocyte responsiveness to Mycobacterium leprae antigens in association with HLA-DR3.

Authors:  W van Eden; B G Elferink; R R de Vries; D L Leiker; J J van Rood
Journal:  Clin Exp Immunol       Date:  1984-01       Impact factor: 4.330

6.  Cellular immune response to the cell walls of Mycobacterium leprae in leprosy patients and healthy subjects exposed to leprosy.

Authors:  P W Roche; K D Neupane; W J Britton
Journal:  Clin Exp Immunol       Date:  1992-07       Impact factor: 4.330

7.  Suppression of delayed hypersensitivity skin reactions to tuberculin by M. leprae antigens in patients with lepromatous and tuberculoid leprosy.

Authors:  U Sengupta; S Sinha; G Ramu; J Lamb; J Ivanyi
Journal:  Clin Exp Immunol       Date:  1987-04       Impact factor: 4.330

8.  Dominant cell wall proteins of Mycobacterium leprae recognized by monoclonal antibodies.

Authors:  W J Britton; L Hellqvist; R J Garsia; A Basten
Journal:  Clin Exp Immunol       Date:  1987-01       Impact factor: 4.330

9.  Effect of purified protein derivative and sonicates of Mycobacterium leprae and Mycobacterium bovis BCG on thromboplastin response in human monocytes in vitro.

Authors:  T Lyberg; O Closs; H Prydz
Journal:  Infect Immun       Date:  1982-12       Impact factor: 3.441

10.  Cellular and humoral immune responses to recombinant 65-kD antigen of Mycobacterium leprae in leprosy patients and healthy controls.

Authors:  S Ilangumaran; N P Shanker Narayan; G Ramu; V R Muthukkaruppan
Journal:  Clin Exp Immunol       Date:  1994-04       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.